David A Roth

5PUBLICATIONS
33CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)PharmacogenomicsClinical pharmacology and therapeuticsAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 27, 2022
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.

Richard Furie, Brad H Rovin, Frédéric Houssiau

|Apr 16, 2022
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.

Fengchun Zhang, Jie Zheng, Yang Li

|Sep 17, 2021
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.

Hermine I Brunner, Carlos Abud-Mendoza, Masaaki Mori

|Jul 03, 2021
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.

Yoshiya Tanaka, Sang-Cheol Bae, Damon Bass

|Feb 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.

Daniel J Wallace, Ellen M Ginzler, Joan T Merrill

Pageof 1

Frequent Collaborators

3 joint publications

Richard Furie

3 joint publications

Beulah N Ji

3 joint publications

Damon L Bass

2 joint publications

Paige Meizlik